Literature DB >> 31901289

[Immunisation schedule of the Spanish Association of Paediatrics: 2020 recommendations].

Francisco José Álvarez García1, María José Cilleruelo Ortega2, Javier Álvarez Aldeán3, María Garcés-Sánchez4, Nuria García Sánchez5, Elisa Garrote Llanos6, Ángel Hernández Merino7, Antonio Iofrío de Arce8, Manuel Merino Moína9, Abián Montesdeoca Melián10, María Luisa Navarro Gómez11, Jesús Ruiz-Contreras12.   

Abstract

The CAV-AEP annually publishes the immunisation schedule considered optimal for all children resident in Spain, taking into account the available evidence. The 2+1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate. A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2+1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks. Rotavirus vaccine should be systematic for all infants. Meningococcal B vaccine, with a 2+1 schedule, should be included in routine calendar. In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups. Two-dose schedules for MMR (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine. Universal systematic vaccination against HPV is recommended, both for girls and boys, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders.
Copyright © 2019 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adolescent; Adolescente; Calendario de vacunación; Child; Enfermedades inmunoprevenibles; Immunisation schedule; Infant; Lactante; Niño; Vaccine preventable diseases; Vaccines; Vacunas

Mesh:

Substances:

Year:  2020        PMID: 31901289     DOI: 10.1016/j.anpedi.2019.10.007

Source DB:  PubMed          Journal:  An Pediatr (Engl Ed)        ISSN: 2341-2879


  4 in total

Review 1.  Update on the Epidemiological Features and Clinical Implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) Coinfection.

Authors:  Alexandre Pérez-González; Edward Cachay; Antonio Ocampo; Eva Poveda
Journal:  Microorganisms       Date:  2022-05-18

2.  A surface plasmon resonance based approach for measuring response to pneumococcal vaccine.

Authors:  Marta Garrido-Jareño; Leonor Puchades-Carrasco; Leticia Orti-Pérez; José Miguel Sahuquillo-Arce; María Del Carmen Meyer-García; Joan Mollar-Maseres; Carmina Lloret-Sos; Ana Gil-Brusola; José Luis López-Hontangas; José Manuel Beltrán-Garrido; Javier Pemán-García; Antonio Pineda-Lucena
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

3.  Hospitalizations related to meningococcal infection in Spain from 1997 to 2018.

Authors:  Stefan Walter; Ruth Gil-Prieto; Mario Gil-Conesa; Gil Rodriguez-Caravaca; Jesús San Román; Angel Gil de Miguel
Journal:  BMC Infect Dis       Date:  2021-12-06       Impact factor: 3.090

4.  Factors influencing HPV knowledge and vaccine acceptability in parents of adolescent children: results from a survey-based study (KAPPAS study).

Authors:  Noelia López; Ignacio Salamanca de la Cueva; Edelmiro Vergés; Eva Suárez Vicent; Almudena Sánchez; Ana Belén López; María Belén Panizo-Santos; María Garcés-Sánchez; Abián Montesdeoca; Antonio José Rivera; Manuel Suárez Cotarelo
Journal:  Hum Vaccin Immunother       Date:  2022-02-01       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.